TY - JOUR
T1 - International Study of the Epidemiology of Platelet Transfusions in Critically Ill Children with an Underlying Oncologic Diagnosis
AU - on behalf of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, Pediatric Critical Care Blood Research Network (BloodNet), and the Point Prevalence Study of Platelet Transfusions in Critically Ill Children (P3T) Investigators
AU - Nellis, Marianne E.
AU - Goel, Ruchika
AU - Karam, Oliver
AU - Cushing, Melissa M.
AU - Davis, Peter J.
AU - Steiner, Marie E.
AU - Tucci, Marisa
AU - Stanworth, Simon J.
AU - Spinella, Philip C.
AU - Butt, Warwick
AU - Delzoppo, Carmel
AU - Erickson, Simon
AU - Croston, Elizabeth
AU - Barr, Samantha
AU - Cavazzoni, Elena
AU - de Jaeger, Annick
AU - French, Mary Ellen
AU - Ropars, Marion
AU - Clayton, Lucy
AU - Murthy, Srinivas
AU - Krahn, Gordon
AU - Qu, Dong
AU - Hui, Yi
AU - Johansen, Mathias
AU - Jensen, Anne Mette Baek
AU - Jarnvig, Inge Lise
AU - Strange, Ditte
AU - Jayashree, Muralidharan
AU - Reddy, Mounika
AU - Sankar, Jhuma
AU - Vijay Kumar, U.
AU - Lodha, Rakesh
AU - Lerner, Reut Kassif
AU - Paret, Gideon
AU - Schiller, Ofer
AU - Shostak, Eran
AU - Dagan, Ovadia
AU - Cavari, Yuval
AU - Chiusolo, Fabrizio
AU - Cillis, Annagrazia
AU - Camporesi, Anna
AU - Kneyber, Martin
AU - Otter, Suzan Cochius Den
AU - Van Hemeldonck, Ellen
AU - Beca, John
AU - Sherring, Claire
AU - Rea, Miriam
AU - Abadesso, Clara
AU - Moniz, Marta
AU - Alshehri, Saleh
N1 - Publisher Copyright:
© 2019 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Objectives: To describe the epidemiology of platelet transfusions in critically ill children with an underlying oncologic diagnosis and to examine effects of prophylactic versus therapeutic transfusions. Design: Subgroup analysis of a prospective, observational study. Setting: Eighty-two PICUs in 16 countries. Patients: All children (3 d to 16 yr old) who received a platelet transfusion during one of the six predefined screening weeks and had received chemotherapy in the previous 6 months or had undergone hematopoietic stem cell transplantation in the last year. Interventions: None. Measurements and Main Results: Of the 548 patients enrolled in the parent study, 237 (43%) had an underlying oncologic diagnosis. In this population, 71% (168/237) of transfusions were given prophylactically, and 59% (139/237) of transfusions were given at a total platelet count greater than 20 × 109/L, higher than the current recommendations. Those with an underlying oncologic diagnosis were significantly older, and received less support including less mechanical ventilation, fewer medications that affect platelet function, and less use of extracorporeal life support than those without an underlying oncologic diagnosis. In this subpopulation, there were no statistically significant differences in median (interquartile range) platelet transfusion thresholds when comparing bleeding or nonbleeding patients (50 × 109/L [10-50 × 109/L] and 30 × 109/L [10-50 × 109/L], respectively [p = 0.166]). The median (interquartile range) interval transfusion increment in children with an underlying oncologic diagnosis was 17 × 109/L (6-52 × 109/L). The presence of an underlying oncologic diagnosis was associated with a poor platelet increment response to platelet transfusion in this cohort (adjusted odds ratio, 0.46; 95% CI, 0.22-0.95; p = 0.035). Conclusions: Children with an underlying oncologic diagnosis receive nearly half of platelet transfusions prescribed by pediatric intensivists. Over half of these transfusions are prescribed at total platelet count greater than current recommendations. Studies must be done to clarify appropriate indications for platelet transfusions in this vulnerable population.
AB - Objectives: To describe the epidemiology of platelet transfusions in critically ill children with an underlying oncologic diagnosis and to examine effects of prophylactic versus therapeutic transfusions. Design: Subgroup analysis of a prospective, observational study. Setting: Eighty-two PICUs in 16 countries. Patients: All children (3 d to 16 yr old) who received a platelet transfusion during one of the six predefined screening weeks and had received chemotherapy in the previous 6 months or had undergone hematopoietic stem cell transplantation in the last year. Interventions: None. Measurements and Main Results: Of the 548 patients enrolled in the parent study, 237 (43%) had an underlying oncologic diagnosis. In this population, 71% (168/237) of transfusions were given prophylactically, and 59% (139/237) of transfusions were given at a total platelet count greater than 20 × 109/L, higher than the current recommendations. Those with an underlying oncologic diagnosis were significantly older, and received less support including less mechanical ventilation, fewer medications that affect platelet function, and less use of extracorporeal life support than those without an underlying oncologic diagnosis. In this subpopulation, there were no statistically significant differences in median (interquartile range) platelet transfusion thresholds when comparing bleeding or nonbleeding patients (50 × 109/L [10-50 × 109/L] and 30 × 109/L [10-50 × 109/L], respectively [p = 0.166]). The median (interquartile range) interval transfusion increment in children with an underlying oncologic diagnosis was 17 × 109/L (6-52 × 109/L). The presence of an underlying oncologic diagnosis was associated with a poor platelet increment response to platelet transfusion in this cohort (adjusted odds ratio, 0.46; 95% CI, 0.22-0.95; p = 0.035). Conclusions: Children with an underlying oncologic diagnosis receive nearly half of platelet transfusions prescribed by pediatric intensivists. Over half of these transfusions are prescribed at total platelet count greater than current recommendations. Studies must be done to clarify appropriate indications for platelet transfusions in this vulnerable population.
KW - cancer
KW - critical illness
KW - hematopoietic stem cell transplant
KW - pediatrics
KW - platelet transfusion
UR - http://www.scopus.com/inward/record.url?scp=85069274501&partnerID=8YFLogxK
U2 - 10.1097/PCC.0000000000001987
DO - 10.1097/PCC.0000000000001987
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31107379
AN - SCOPUS:85069274501
SN - 1529-7535
VL - 20
SP - e342-e351
JO - Pediatric Critical Care Medicine
JF - Pediatric Critical Care Medicine
IS - 7
ER -